Team ArchbowJan 30Is a Direct-to-Patient Access Model Viable For My Product?Is a Direct-to-Patient Access Model Viable For My Product?
Team ArchbowAug 31, 2023Five Takeaways from Medicare's 10 Drugs Up for Price NegotiationFive Takeaways from Medicare's 10 Drugs Up for Price Negotiation
Kristy FrizzoSep 23, 2022Best Practices for Improving Program Performance Through Well-Managed SP RelationshipsWith a carefully crafted approach, SPs & Manufacturers can enjoy partnerships that drive access, adherence, and overall program performance
Kelly RatliffAug 30, 2022Control vs. Access: Why Clinical Characteristics Should Guide Specialty Pharmacy StrategyWhen it comes to pharmacy network design, there is a careful balance between access and control.
Mike PolandMar 29, 2022Maximizing Specialty Pharmacy ContractsWhen approached strategically, contracting with SP networks can positively impact patient experience and the company’s bottom line.
Grace BerginMar 14, 2022What the CMS Final Rule on Copay Programs Means for Pharmaceutical ManufacturersIt is vital for pharmaceutical manufacturers to consider how much financial and reputational risk they may face as a result of the pending C
Kristy FrizzoFeb 7, 20229 Considerations When Designing Your Specialty Pharmacy Network A proven, reliable methodology for designing a specialty pharmacy network is essential to ensuring optimal patient access